Abstract Library

#4647 Crosstalk between cancer-associated fibroblasts and small intestinal neuroendocrine tumour cells in a 3D spheroid model

Introduction: At diagnosis, over 50% of small intestinal neuroendocrine tumours (SI-NETs) have metastasised to the mesentery where they often induce extensive fibrosis. Recent studies highlight the crucial interaction between SI-NET cells and cancer-associated fibroblasts (CAFs) in the pathogenesis of mesenteric fibrosis (MF).

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, van Koetsveld P, Iyer A, Hofland J,

Keywords: mesenteric fibrosis, small intestinal neuroendocrine tumour, CAF,

#3774 The role of the gut microbiome in patients with midgut neuroendocrine tumors

Introduction: When compared to other cancers, the prevalence of midgut neuroendocrine tumors (NETs) has disproportionally increased over the past decades. To date, very little progress has been made in the discovery of (epi)genetic drivers and treatment options of these tumors. Recent microbiome research has provided novel treatment targets among various cancer types. However, its role in midgut NETs and the Carcinoid Syndrome (CS), a frequently present syndrome of hormonal hypersecretion, has not been studied.

Conference:

Presenting Author:

Authors: Mulders M, Audhoe A, Kraaij R, van Koetsveld P, Feelders R,

Keywords: gut, microbiome, neuroendocrine, tumor, carcinoid, syndrome, diagnosis,

#3464 Digital quantification of somatostatin receptor subtype 2 immunostaining in pancreatic neuroendocrine tumors and GH-secreting adenoma: A validation study

Introduction: Somatostatin receptor subtype 2 (SST2) immunostaining (IHC) is routinely performed in neuroendocrine tumors (NET) and recommended in acromegaly guidelines. No univocal score of SST2 IHC has been validated yet.

Conference:

Presenting Author: Campana C

Authors: Campana C, van Koetsveld P, Iyer A, van Velthuysen M, van den Dungen E,

Keywords: SST2, digital image analysis, panNET, staining intensity, percentage of positive cell,

#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1

Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Iyer A

Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,

Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,

#2988 Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells

Introduction: The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Klomp I

Authors: Klomp I, Dalm S, van Koetsveld P, Dogan-Oruç F, de Jong M,

Keywords: neuroendocrine tumors, bon-1, epigenetic, histone, histone deacetylase inhibitor, HDACi, upregulation, reversibility, somatostatin receptor-2, somatostatin,